C07K14/22

GNA1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis
20210308247 · 2021-10-07 ·

The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.

Glycoconjugation process

The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.

Glycoconjugation process

The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.

MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES
20210277069 · 2021-09-09 ·

The present invention provides mutated fHbp polypeptides and fusion proteins comprising said mutated fHbp polypeptides that are useful as components of immunogenic compositions for immunizing against Neisseria meningitidis infection.

MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES
20210277069 · 2021-09-09 ·

The present invention provides mutated fHbp polypeptides and fusion proteins comprising said mutated fHbp polypeptides that are useful as components of immunogenic compositions for immunizing against Neisseria meningitidis infection.

Bacterial polysaccharide-conjugated carrier proteins and use thereof

Immunogenic compositions that include a bacterial capsular polysaccharide conjugated to a carrier protein are described. In some embodiments, the bacterial capsular polysaccharide is a Neisseria meningitidis capsular polysaccharide. The carrier protein includes an N. meningitidis factor H binding protein (fHbp) linked to cholera toxin subunit B (CTB). Administration of the immunogenic compositions elicits an immune response that includes production of meningococcal polysaccharide-specific and fHbp-specific antibodies. Use of the immunogenic compositions as meningococcal vaccines is also described.

Non-lipidated variants of <i>Neisseria meningitidis </i>ORF2086 antigens

The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis, and methods related thereto.

Non-lipidated variants of <i>Neisseria meningitidis </i>ORF2086 antigens

The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis, and methods related thereto.

Modified meningococcal fHbp polypeptides

The inventors have identified residues within variant 2 and variant 3 of meningococcal fHbp which can be modified to enhance their properties.

Modified meningococcal fHbp polypeptides

The inventors have identified residues within variant 2 and variant 3 of meningococcal fHbp which can be modified to enhance their properties.